Literature DB >> 25341795

Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease.

Susanne Karbach1, Andrew L Croxford2, Matthias Oelze2, Rebecca Schüler2, Daniel Minwegen2, Joanna Wegner2, Lija Koukes2, Nir Yogev2, Alexei Nikolaev2, Sonja Reißig2, Alexander Ullmann2, Maike Knorr2, Maximilian Waldner2, Markus F Neurath2, Huige Li2, Zhixiong Wu2, Christoph Brochhausen2, Jürgen Scheller2, Stefan Rose-John2, Carolin Piotrowski2, Ingo Bechmann2, Markus Radsak2, Philipp Wild2, Andreas Daiber2, Esther von Stebut2, Philip Wenzel2, Ari Waisman1, Thomas Münzel2.   

Abstract

OBJECTIVE: Interleukin (IL)-17A is regarded as an important cytokine to drive psoriasis, an inflammatory skin disease marked by increased cardiovascular mortality. We aimed to test the hypothesis that overproduction of IL-17A in the skin leading to dermal inflammation may systemically cause vascular dysfunction in psoriasis-like skin disease. APPROACH AND
RESULTS: Conditional overexpression of IL-17A in keratinocytes caused severe psoriasis-like skin inflammation in mice (K14-IL-17A(ind/+) mice), associated with increased reactive oxygen species formation and circulating CD11b(+) inflammatory leukocytes in blood, with endothelial dysfunction, increased systolic blood pressure, left ventricular hypertrophy, and reduced survival compared with controls. In K14-IL-17A(ind/+) mice, immunohistochemistry and flow cytometry revealed increased vascular production of the nitric oxide/superoxide reaction product peroxynitrite and infiltration of the vasculature with myeloperoxidase(+)CD11b(+)GR1(+)F4/80(-) cells accompanied by increased expression of the inducible nitric oxide synthase and the nicotinamide dinucleotide phosphate (NADPH) oxidase, nox2. Neutrophil depletion by anti-GR-1 antibody injections reduced oxidative stress in blood and vessels. Neutralization of tumor necrosis factor-α and IL-6 (both downstream of IL-17A) reduced skin lesions, attenuated oxidative stress in heart and blood, and partially improved endothelial dysfunction in K14-IL-17A(ind/+) mice.
CONCLUSIONS: Dermal overexpression of IL-17A induces systemic endothelial dysfunction, vascular oxidative stress, arterial hypertension, and increases mortality mainly driven by myeloperoxidase(+)CD11b(+)GR1(+)F4/80(-) inflammatory cells. Depletion of the GR-1(+) immune cells or neutralization of IL-17A downstream cytokines by biologicals attenuates the vascular phenotype in K14-IL-17A(ind/+) mice.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  animal model of human disease; immune system; inflammation; vascular dysfunction

Mesh:

Substances:

Year:  2014        PMID: 25341795     DOI: 10.1161/ATVBAHA.114.304108

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  78 in total

Review 1.  Interactions of hyperhomocysteinemia and T cell immunity in causation of hypertension.

Authors:  Sudhakar Veeranki; Siva K Gandhapudi; Suresh C Tyagi
Journal:  Can J Physiol Pharmacol       Date:  2016-04-28       Impact factor: 2.273

Review 2.  Immune Mechanisms in Arterial Hypertension.

Authors:  Ulrich Wenzel; Jan Eric Turner; Christian Krebs; Christian Kurts; David G Harrison; Heimo Ehmke
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

3.  Ly6C+ Inflammatory Monocyte Differentiation Partially Mediates Hyperhomocysteinemia-Induced Vascular Dysfunction in Type 2 Diabetic db/db Mice.

Authors:  Pu Fang 方璞; Xinyuan Li 李欣源; Huimin Shan 单慧敏; Jason J Saredy; Ramon Cueto; Jixiang Xia 夏继祥; Xiaohua Jiang 蒋晓华; Xiao-Feng Yang 杨晓峰; Hong Wang 王虹
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-01       Impact factor: 8.311

4.  IL-6 Trans-Signaling Drives Murine Crescentic GN.

Authors:  Gerald S Braun; Yoshikuni Nagayama; Yuichi Maruta; Felix Heymann; Claudia R van Roeyen; Barbara M Klinkhammer; Peter Boor; Luigi Villa; David J Salant; Ute Raffetseder; Stefan Rose-John; Tammo Ostendorf; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2015-06-03       Impact factor: 10.121

5.  Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1.

Authors:  Michael S Garshick; Michael Tawil; Tessa J Barrett; Charissa M Salud-Gnilo; Michael Eppler; Angela Lee; Jose U Scher; Andrea L Neimann; Sanja Jelic; Nehal N Mehta; Edward A Fisher; James G Krueger; Jeffrey S Berger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-05       Impact factor: 8.311

6.  Inflammasome Signaling and Impaired Vascular Health in Psoriasis.

Authors:  Michael S Garshick; Tessa J Barrett; Todd Wechter; Sarah Azarchi; Jose U Scher; Andrea Neimann; Stuart Katz; Judilyn Fuentes-Duculan; Maria V Cannizzaro; Sanja Jelic; Edward A Fisher; James G Krueger; Jeffrey S Berger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

7.  IL-17 Induces MPTP opening through ERK2 and P53 signaling pathway in human platelets.

Authors:  Jing Yuan; Pei-Wu Ding; Miao Yu; Shao-Shao Zhang; Qi Long; Xiang Cheng; Yu-Hua Liao; Min Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

8.  Abnormal CD161+ immune cells and retinoic acid receptor-related orphan receptor γt-mediate enhanced IL-17F expression in the setting of genetic hypertension.

Authors:  Madhu V Singh; Michael Z Cicha; Santosh Kumar; David K Meyerholz; Kaikobad Irani; Mark W Chapleau; François M Abboud
Journal:  J Allergy Clin Immunol       Date:  2017-01-16       Impact factor: 10.793

9.  Psoriasis and cardiovascular disorders: association or epiphenomenon? Meta-analysis of observational studies.

Authors:  Saumya Choudhary; Rachana Patel; Dibyabhaba Pradhan; Ravi Deval; Harpreet Singh; George Thomas; Arun Kumar Jain
Journal:  3 Biotech       Date:  2020-02-07       Impact factor: 2.406

10.  Interleukin 6 regulates psoriasiform inflammation-associated thrombosis.

Authors:  Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.